Penumbra (PEN) to Release Quarterly Earnings on Thursday

Penumbra (NYSE:PEN) is expected to be announcing its earnings results after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of $0.88 per share for the quarter. Penumbra has set its FY 2025 guidance at EPS.Investors that are interested in participating in the company’s conference call can do so using this link.

Penumbra (NYSE:PEN) last issued its earnings results on Tuesday, February 18th. The company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.09. The business had revenue of $315.52 million during the quarter, compared to analyst estimates of $311.63 million. Penumbra had a return on equity of 8.99% and a net margin of 2.97%. On average, analysts expect Penumbra to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Penumbra Stock Up 12.0 %

Shares of PEN opened at $303.55 on Thursday. The firm has a market cap of $11.65 billion, a P/E ratio of 352.97, a P/E/G ratio of 1.97 and a beta of 0.53. The stock has a 50 day simple moving average of $256.15 and a two-hundred day simple moving average of $225.97. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.82 and a quick ratio of 3.25. Penumbra has a 1 year low of $148.00 and a 1 year high of $310.00.

Insider Activity at Penumbra

In related news, CEO Adam Elsesser sold 15,000 shares of the stock in a transaction on Friday, December 20th. The stock was sold at an average price of $242.96, for a total transaction of $3,644,400.00. Following the sale, the chief executive officer now directly owns 837,582 shares of the company’s stock, valued at $203,498,922.72. This trade represents a 1.76 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Harpreet Grewal sold 167 shares of the stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $241.28, for a total value of $40,293.76. Following the sale, the director now directly owns 8,530 shares in the company, valued at $2,058,118.40. This trade represents a 1.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 18,219 shares of company stock worth $4,426,439 over the last quarter. 5.00% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Truist Financial upped their target price on Penumbra from $285.00 to $325.00 and gave the stock a “buy” rating in a research note on Wednesday. Robert W. Baird upped their target price on Penumbra from $305.00 to $328.00 and gave the stock an “outperform” rating in a research note on Wednesday. Morgan Stanley boosted their price objective on Penumbra from $240.00 to $260.00 and gave the company an “equal weight” rating in a research report on Wednesday. Needham & Company LLC reiterated a “hold” rating on shares of Penumbra in a research report on Wednesday. Finally, Piper Sandler reiterated an “overweight” rating and issued a $330.00 price objective (up previously from $250.00) on shares of Penumbra in a research report on Wednesday. Three research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $292.64.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.